The complete nucleotide sequences of the human papillomavirus type 16 (HPV-16) variants present in the CaSki and SiHa cervical carcinoma cell lines and the primary subgenomic HPV-18 variant present in the HeLa cervical carcinoma cell line were determined using overlapping bulk PCR products as templates. PCR-based methods were also used to characterize five previously unreported CaSki HPV-16 genomic disruptions and the 5h cellular-viral junction common to all HeLa HPV-18 subgenomic structures.
Introduction
Human papillomavirus (HPV) type 16 and type 18 genotypes account for greater than 65 % of all HPV DNApositive invasive cervical carcinomas in multi-institutional studies (Bosch et al., 1995 ; Lorincz et al., 1992) and are found in the majority of human cervical carcinoma-derived cell lines (Boshart et al., 1984 ; Pater & Pater, 1985 ; Schwarz et al., 1985 ; Yee et al., 1985) , where integration disrupting the HPV E1 or E2 open reading frame (ORF) while preserving the E6 and E7 ORFs is a common, although not exclusive, finding.
Initial and current descriptive studies of HPV-16 and HPV-18 in clinical samples and cell lines provide the basis for hypotheses ranging from genesis of variants (Chan et al., 1992 ; Ong et al., 1993 ; Yamada et al., 1997) to tumorigenesis from overexpression of E6 and E7 oncoproteins (for review see zur Hausen, 1994) . Because of commercial availability, known biological and genetic properties and stability of their respective endogenous HPV genomes on repeated passage, the cervical carcinoma cell lines CaSki, SiHa and HeLa (Table 1) are frequently utilized as model systems for examining viral and cellular protein-protein (Hu et al., 1997) or DNA-protein (Tan et al., 1998) e-mail jdmeissner!hotmail.com diagnostics (Adler et al., 1997) or potential therapeutics (Lappalainen et al., 1996) .
On a practical level, observations made using HPVcontaining cervical carcinoma cell lines are only relevant to proposed oncogenic sequelae of HPV infection or provisional treatment guidelines insofar as : (1) the HPV sequences in these cell lines represent once-circulating or still-circulating genomes ; (2) potentially pathogenic changes in HPV genomic physical state or phenotype identified in these cell lines are not an artifact of medical intervention or cell culture. Before assessing whether the particular sequences or physical states of HPV genomes in cell lines fully satisfy these conditions, it is essential that complete, correct sequences have been determined and physical states adequately described.
PCR as applied to mucosal HPV typing or determination of physical state(s) typically involves amplification of discrete subgenomic regions using either degenerate or type-specific primers. Long PCR has been used to determine the sequence of a novel HPV type (Forslund & Hansson, 1996) or to amplify and partially sequence full-length genomes of known or novel HPV types . However, the estimated error rate in these latter studies was one misincorporation every 700-800 bp.
To reduce the influence of Taq polymerase artefacts on sequence determination, sets of closely spaced, overlapping primer pairs covering the entire HPV-16 and HPV-18 genomes were designed, and PCR amplicons generated by these primer pairs directly sequenced. The application of these primer libraries to sequence determination and physical state charac- et al. (1992) , Mincheva et al. (1987) , Popescu & DiPaolo (1989) .
terization of HPV variants in routinely used cervical carcinoma cell lines is reported here.
Methods
HPV DNA clones. CaSki HPV-16 clones p894, p895 and p896 (for descriptions see Baker et al., 1987) were generously provided by C. Baker.
Cell lines. CaSki (ATCC CRL 1550), SiHa (ATCC HTB35) and HeLa (ATCC CCL2) cervical carcinoma cell lines were obtained from the ATCC. Cells were cultured and DNA was isolated using standard methods (Sambrook et al., 1989) .
Oligonucleotide primers. Primer pairs (sequences available on request) were designed to span the entire HPV-16 and HPV-18 genomes at 350-500 nucleotide (nt) intervals. In general, 18-21-mers with a GjC content of 40-60 % were selected, and primers with a 3h-terminal base at nucleotide positions previously reported to vary in HPV-16 and HPV-18 isolates were avoided.
PCR. This was performed using the GenAmp PCR Reagents kit with AmpliTaq DNA polymerase (Perkin Elmer Cetus) according to the manufacturer's instructions, using 50 µl reaction volumes. Amplicons of up to 2 kb could be generated under these conditions, although an upper limit was not rigorously evaluated. In one instance, at adjoining integration sites of the HPV-18 variant in HeLa cells, a primer combination in conjunction with long PCR was required to amplify a fragment predicted to be larger than 4 kb. For this amplification, the Expand Long Template PCR system (Boehringer Mannheim) was used, following the manufacturer's suggested reaction cocktail mixes and cycling parameters.
Automated dye-terminator DNA sequencing.This was performed using the ABI Prism Dye Terminator Cycle Sequencing Ready Reaction kit with AmpliTaq DNA polymerase, FS (Perkin Elmer Cetus) with cycling parameters as per supplied protocol. Electrophoresis and analysis were performed using the ABI model 373 DNA sequencer (Applied Biosystems). For all amplicons, sequence was determined on both strands. The only troublesome artifact routinely noted was a small, often ambiguous peak following an A peak, which in every case proved to be a G ; a dropout peak following an A peak may be diagnostic for a G at this position using the modified AmpliTaq polymerase (Parker et al., 1996) .
Manual sequencing. Manual sequencing of CaSki clone p895 (Baker et al., 1987) utilizing the dideoxynucleotide chain termination method (Sanger et al., 1977) was performed with Redivue $&S-dATP (Amersham) and the Sequenase version 2.0 DNA sequencing kit (United States Biochemical) according to the manufacturers' instructions.
Results

Sequencing of the bulk HPV-16 DNA amplified from CaSki and SiHa cells
The left side of Fig. 1 lists the 30 point mutations and the single 1 nt deletion in CaSki HPV-16 relative the to HPV-16R reference sequence. Seven of these point mutations have been previously noted in CaSki HPV-16 partial sequence determinations using PCR-based methods (Chan et al., 1992 ; Icenogle et al., 1991 ; Xi et al., 1997 ; D. Galutira, personal communication) . No additional mutations were found in these previously sequenced regions. Seventeen of the 30 point mutations identified in CaSki HPV-16 have been reported in other HPV-16 variants (Human Papillomaviruses, 1996) , and most of the remaining mutations are in ORFs or regions of ORFs where few or no variants have been sequenced. Eleven of the 13 point mutations in CaSki HPV-16 early region codons are nonsilent, and seven of the 11 amino acid replacements in the early region are nonconservative. One- (Maki et al., 1996) were sequenced on both strands, but given the length of (and sequencing trace deterioration beyond) the poly(T) run, the potential for polymerase-induced artifact exists.
third of the mutations and the single nucleotide deletion are concentrated in noncoding regions, with all of the changes in the short noncoding region (SNR) (Maki et al., 1996) [also referred to as the late upstream region or LUR (Geisen & Kahn, 1996) ] occurring within a 51 nt span. The estimated copy number of the HPV-16 variant in CaSki cells is 60-600 (Yee et al., 1985) , yet no evidence of heterogeneity at any nucleotide position in the sequenced CaSki HPV-16 amplicons was found. All mutations identified in CaSki HPV-16 genomic DNA by automated sequencing were found on manual sequencing of the corresponding regions of CaSki HPV-16 clone p895 (Baker et al., 1987) , with no additional changes noted.
The right side of Fig. 1 lists the 23 point mutations and the SNR 2 nt deletion present in the SiHa HPV-16 genome, along with the larger E2\E4 and long control region (LCR) deletions previously identified (Baker et al., 1987 ; Chan et al., 1992 ; El Awady et al., 1987) and the portion of the E2\E4 region deleted upon integration. Nine of these point mutations have been reported in prior partial SiHa HPV-16 sequence determinations (Fig. 2) , and 11 of the mutations are shared with CaSki HPV-16. As with CaSki HPV-16, the great majority of changes in the early region are nonsilent, although six of the 11 deduced amino acid substitutions in this region of the SiHa HPV-16 genome are conservative.
Identification of rearranged CaSki HPV-16 genomes
The HPV-16 variant in CaSki cells consists of full-length genomes as well as rearranged genomic structures (Pater & Pater, 1985 ; Yee et al., 1985) . Three clones (designated as p894 through p896) obtained from a BamHI digest of CaSki cellular DNA yielding full-length and numerous off-size HPV genomic fragments have been previously partially characterized (Baker et al., 1987) . Clone p894 contains the full-length HPV-16 variant genome, while clones p895 and p896 contain supraand subgenomic structures, respectively (Fig. 3) . The deletion junction represented by p896 and the right noncontiguous viral junction of p895 (nt 4588\2032) were amplified from CaSki cellular DNA using primer combinations based on previously determined restriction maps. These amplicons were directly sequenced, and the proposed junctional nucleotides confirmed in the respective clones by manual sequencing.
The putative left noncontiguous viral junction of clone p895 (Baker et al., 1987) was absent using a primer combination presumed to flank it, i.e. the sequence of the PCR amplicon in this region using p895 as a template was uninterrupted. Manual sequencing of p895 using a primer downstream of nt 2032 on the complementary strand generated a mixture of two sequences, the resolution of which indicated that clone p895 represents either a duplication of nt 2032-4588 or a deletion from nt 4589-2031 (Fig. 3 ) in a subpopulation of CaSki HPV-16 head-to-tail concatemers.
Additional primer combinations flanking the single BamHI site at nt 6152 were selected to amplify HPV-16 genomic structures in CaSki cellular DNA which might have been missed in cloning experiments utilizing BamHI digests. The primer combinations were separated by more than 2 kb and would not be expected to generate amplicons under the cycling conditions used unless genomic alterations had occurred. These amplifications were reproducible using the same combination or a different combination of primers flanking a particular junction. In the absence of cloning, no determination of the mutational event(s) responsible for these noncontiguous viral junctions (Fig. 3) can be made, although junctions 2 and 3 likely represent the left and right sides of an insertion. Amplification attempts using primer combinations with both primers hybridizing to the same strand to identify potential head-to-head rearrangement events were unsuccessful.
Sequence of the bulk HPV-18 DNA amplified from HeLa cells
All of the HPV-18 genomes in HeLa cells are truncated (Schwarz et al., 1985) , so a complete nucleotide sequence of the HPV-18 variant initially infecting patient HeLa cannot be determined. The 19 point mutations (out of 5209 nt sequenced) in HeLa HPV-18 compared to the reference clone sequence CaSki, SiHa and HeLa HPV sequences CaSki, SiHa and HeLa HPV sequences Baker et al. (1987) for further details] whose junctional nucleotides were determined in this study. Nucleotide positions refer to the HPV-16R sequence (see Fig. 1 legend) and indicate the last identical nucleotide position on the left or right side of the junction. Dashed lines fill in hypothetical precursors of these structures. As explained in the text, the structure represented by p895, a clone with a CaSki HPV-16 insert of " 10n5 kb, could have arisen either by a duplication of nt 2032-4588 or by the deletion depicted here. (B) CaSki HPV-16 head-to-tail noncontiguous viral junctions. The six HPV nucleotides abutting each junction are shown, although in every case at least 100 nt of sequence on either side of the junction was determined, allowing for unambiguous alignment. In structures 3, 4 and 5, nonviral nucleotides interpolated between viral-viral junctions are shown replacing the ' deleted ' portions of the hypothetical precursor genomes. The continuation of the HPV-16R sequence to nt 3229 is shown below structure 5 for comparison. (Baker, 1993 ; Cole & Danos, 1987 ; Meissner, 1993) are listed in Fig. 4 . One-third of the mutations in the HeLa HPV-18 genomic remnants occur in the LCR. In contrast to the CaSki and SiHa HPV-16 variants, the majority of changes in HeLa HPV-18 early region codons are silent.
Amplification of HeLa HPV-18 integration sites
Attempts to identify noncontiguous viral junctions in HeLa HPV-18 genomes using a variety of primer combinations and standard cycling parameters were unsuccessful. One primer combination in conjunction with long PCR, however, successfully amplified a " 4 kb region of cellular DNA flanked by upstream and downstream HPV-18 DNA, previously characterized by restriction mapping of an HPV-18 positive clone from a HeLa genomic library (Picken & Yang, 1987) .
The viral-cellular junction at nt 25 in HeLa II [ Fig. 4 ; subgenomic designations according to Lazo (1988) ] is in close proximity to an Alu repeat element (Swift et al., 1987) . The HeLa IB 5h cellular-viral junction, common to all HeLa HPV-18 subgenomic structures (Lazo, 1988 ; Rosl et al., 1989) , had not been previously sequenced. A repetitive 68 nt pyrimidinepurine tract 330 nt upstream of this junction was identified, with nonrepetitive and noncoding sequence on either side of this repeat.
The putative 3h end of the HeLa IB subgenomic structure, previously reported at nt 2497 from sequence analysis of a cDNA viral-cellular chimera (Inagaki et al., 1988) , was Lazo (1988) . This head-to-tail linkage, interrupted by 4 kb of cellular DNA, is characteristic of at least one chromosomal integration site (Picken & Yang, 1987) . HPV nucleotide positions correspond to the HPV-18 reference sequence (Cole & Danos, 1987) , with flanking cellular sequences numbered according to the convention described in the legend to Fig.  3 . The Alu repeat element and additional repeat elements identified in this study are indicated by solid bars. (A) Nucleotide differences between HeLa HPV-18 determined from assembled PCR amplicons and the HPV-18 reference sequence. Nucleotides which cause nonsilent changes in the deduced amino acid sequences of their respective ORFs are boxed. (B) The upstream pyrimidine-purine tract common to all three HeLa subgenomic cellular-viral junctions (top) and a smaller repeat previously found in a viral-cellular chimeric transcript (Inagaki et al., 1988) and confirmed as the viral-cellular junction of HeLa IB in this study (bottom). The pyrimidine-purine repeats are grouped into repetitive subunits [e.g. (TA) 5 represents TATATATATA]. (C) Previous sequence determination of HeLa HPV-18 DNA or early region mRNA transcripts, including GenBank accession number(s), template used, number of conflicting nucleotides and published references.
confirmed by PCR of HeLa cellular DNA. Determination of the exact viral-cellular junction of subgenomic structure HeLa IA using PCR and degenerate cellular primers was not successful. Characterization based on successful HPV-18 primer pair amplification indicates integration of HeLa IA occurs between nt 3100-3590.
Discussion
The CaSki HPV-16 nucleotide sequence determined by directly sequencing PCR amplicons from CaSki cellular DNA was identical to the sequence determined by manual sequencing of clone p895, a CaSki-derived clone representative of a minority population of the total HPV-16 genomic copies (Baker et al., 1987) . Additionally, the partial sequences for CaSki HPV-16 DNA at noncontiguous viral junctions were identical to the bulk CaSki HPV-16 sequence. It is clear from these results that most, if not all, of the 60-600 distinct HPV-16 variant copies in CaSki cells (Baker et al., 1987 ; Callahan et al., 1992) are derived from the same HPV DNA. No heterogeneity was observed at any nucleotide position in any of the amplicons, and no conflicts were found with previous PCR-based partial CaSki HPV-16 sequence determinations (Chan et al., 1992 ; Icenogle et al., 1991 ; Xi et al., 1997 ; D. Galutira, personal communication) , further supporting the genetic homogeneity of the CaSki HPV-16 variant.
An HPV-16 variant identified as NM.T446 in the European class, subclass G131 (Yamada et al., 1995) , is identical to CaSki BHDA CaSki, SiHa and HeLa HPV sequences CaSki, SiHa and HeLa HPV sequences HPV-16 over the regions sequenced, except for a silent A to C transversion at nt 5328 in the CaSki HPV-16 L2 ORF. Thus, CaSki HPV-16 represents an established, stable and stillcirculating variant, closely related to NM.T446. Alternatively, CaSki HPV-16 is identical to NM.T446, with the single nucleotide difference artefactually caused by radiation-induced mutation (Pattillo et al., 1977 ; Yuan et al., 1995) of the NM.T446 ' founding ' genome in the patient CaSki. The possibility of a sequencing error in NM.T446 has been discounted (C. Wheeler, personal communication) .
No genetic changes in CaSki HPV-16 DNA were found to explain the preferential expression of hybrid E6 and E7 transcripts utilizing a cellular polyadenylation signal and the absence of transcripts from the late region (Smits et al., 1991 ; Smotkin & Wettstein, 1986) . Specifically, compared to the HPV-16R sequence, CaSki HPV-16 has no frameshift or nonsense mutations in any ORFs, and none of the nucleotide changes in CaSki HPV-16 alter established HPV-16 splice donor or acceptor sites, polyadenylation signals or transcription factor binding motifs (Human Papillomaviruses, 1995) . The nucleotide changes in the CaSki HPV-16 SNR in full-length genomes could decrease mRNA stability or affect late promoter activity (Geisen & Kahn, 1996 ; Maki et al., 1996) , but the significance of these changes (or the large number of nonconservative changes in the E1 and E2 ORFs) must be determined by functional studies.
Although the primer pairings used to amplify noncontiguous CaSki HPV DNA were neither completely random nor exhaustive, such that the additional CaSki HPV-16 genomic structures identified may not be representative, it is notable that in six of the seven noncontiguous viral junctions characterized thus far, an early or late polyadenylation signal is eliminated, and in three of the seven the E2 ORF, whose products modulate the activity of the early promoter in HPV-16, is disrupted. Still, because tandem head-to-tail nondisrupted full-length genomes are among the most prevalent of the CaSki HPV-16 copies (Baker et al., 1987) , it is more likely that previously identified factors, e.g. methylation status of the LCR or condensed, transcriptionally inert chromatin in the region of integration (List et al., 1994 ; Rosl et al., 1989 Rosl et al., , 1993 play a larger role in the paucity of mRNA transcripts from the full-length CaSki HPV-16 genomes.
Three SiHa HPV-16 point mutations have not been previously found in any HPV-16 variant, nor has the particular change at nt 5041-42. The T to G change at nt 350 is found in conjunction with an A to G change at nt 131 in CaSki HPV-16 and in a minority of HPV-16 isolates in the European class (Yamada et al., 1997) ; however, a reported SiHa HPV-16 A to G change at nt 131 (Tornesello et al., 1997) was not confirmed in this study. The changes specific to SiHa HPV-16 occurring within coding regions are silent or cause conservative amino acid substitutions, so it is unlikely that they are artefacts caused by cell line establishment or passage. Whether they represent sequencing errors or reflect the under-representation of HPV-16 variant sequences from Asia in the database requires further investigation.
As with CaSki HPV-16, the ' consensus ' sequences determined for the SiHa HPV-16 and HeLa HPV-18 subgenomes using bulk PCR products were unambiguous at all nucleotide positions. However, disagreements with previous partial sequence determinations of SiHa and HeLa variants may indicate that HPV genetic homogeneity in these cell lines is not complete. If there is only one copy of the HPV-16 variant in SiHa cells, any nucleotide disagreements must be artifactual. However, none of four HeLa HPV-18 partial sequences determined from cDNA or DNA clones are identical to sequences from the respective regions in this study (Fig. 4) , and it is difficult to attribute all of these nucleotide conflicts to previous sequencing errors. The adenine at position 169 in this HeLa HPV-18 sequence determination, for example, is a guanine in three different HeLa HPV-18 cDNA clones in one report (Schneider-Gadicke & Schwarz, 1986) , and an adenine in three different HeLa HPV-18 cDNA clones in another report (Inagaki et al., 1988) . If conflicting sequence results occur because of HPV genetic heterogeneity within samples, this is all the more reason to approach HPV typing and characterization with additional vigilance.
The repetitive alternating pyrimidine-purine tract upstream of the 5h viral end common to all HeLa HPV-18 integrated subgenomes represents the fourth such report of HPV integration occurring near (Y-R) N tracts in cervical carcinomas or cell lines (Choo et al., 1996 ; Schneider-Maunoury et al., 1987) . Repeats of this type adopt a Z-DNA configuration and are hypersensitive to nuclease digestion (Pack & Tsurimoto, 1994) , indicating they are conformationally relaxed and perhaps more accessible for integration (Bauer-Hoffman et al., 1996 ; Choo et al., 1996 ; Popescu & DiPaolo, 1989) . Support for preferential HPV integration near repeat units or hypersensitive or fragile sites relies primarily on case reports, and proof will require systematic characterization of HPV integration from a variety of invasive carcinomas. Regardless of whether HPV integration occurs randomly in the cellular genome or preferentially near elements (like Alu repeats) which are themselves ' randomly ' distributed throughout the genome, the proximity of repeat elements to integrated HPV genomes has been exploited to amplify integration junctions in CaSki cells (Carmody et al., 1996) . Random primers and oligomers from the primer libraries reported here are being used to further characterize CaSki HPV-16 DNA from paraffin-embedded specimens obtained prior to radiation treatment of patient CaSki (Pattillo et al., 1977) and to amplify genomes from HPV-16-and HPV-18-positive clinical isolates and anogenital carcinomas.
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